Solid-state characterization of AG337 (Thymitaq), a novel antitumor drug

被引:6
|
作者
Dash, AK [1 ]
Tyle, P [1 ]
机构
[1] AGOURON PHARMACEUT INC,LA JOLLA,CA 92037
关键词
D O I
10.1021/js9500969
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AG337 (Thymitaq) is an antitumor compound synthesized by Agouron Pharmaceuticals, Inc., using protein structure-based drug design. AG337 is a hydrochloride Salt with a molecular formula of C14H12N4OS . 2HCl, This compound was subjected to thermal analyses, Karl Fischer titrimetry, powder X-ray diffractometry, scanning electron microscopy, and FTIR. On the basis of the Karl Fischer and thermogravimetric analysis, it was concluded to be a dihydrate. The differential scanning calorimetric studies revealed, that on heating, AG337 dehydrates and form a metastable form with a melting point of 213 degrees C followed by crystallization into a stable form at 261 degrees C. This stable form was finally melted at 312 degrees C with decomposition. On the basis of the FTIR and HPLC studies, it was concluded that the final exothermic peak at 320 degrees C was due to sample decomposition. The powder X-ray diffraction studies confirmed the existence of these two polymorphs of AG337. Scanning electron microscopic studies revealed that the crystal habits of both the polymorphs were quite different. FTIR spectra of both the polymorphs showed pronounced difference in the range of 600-1800 cm(-1).
引用
收藏
页码:1123 / 1127
页数:5
相关论文
共 50 条
  • [1] Solid-state phase transitions of AG337, an antitumor agent
    Rastogi, S
    Zamansky, I
    Roy, S
    Tyle, P
    Suryanarayanan, R
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 1999, 4 (04) : 623 - 632
  • [2] Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ™) and paclitaxel in patients with advanced solid tumours
    Hughes, AN
    Griffin, MJ
    Calvert, AH
    Johnston, A
    Kerr, B
    Lee, C
    Newell, DR
    Boddy, AV
    ANNALS OF ONCOLOGY, 1998, 9 : 121 - 121
  • [3] Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq™) and paclitaxel
    A N Hughes
    M J Griffin
    D R Newell
    A H Calvert
    A Johnston
    B Kerr
    C Lee
    B Liang
    A V Boddy
    British Journal of Cancer, 2000, 82 (9) : 1519 - 1527
  • [4] Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq™) and paclitaxel
    Hughes, AN
    Griffin, MJ
    Newell, DR
    Calvert, AH
    Johnston, A
    Kerr, B
    Lee, C
    Liang, B
    Boddy, AV
    BRITISH JOURNAL OF CANCER, 2000, 82 (09) : 1519 - 1527
  • [5] A phase II trial of nolatrexed dihydrochloride [Thymitaq, AG337] in patients with advanced hepatocellular carcinoma (HCC)
    Mani, S
    Rosen, L
    Bennett, P
    Dancey, J
    Conner, S
    Johnston, A
    Clendeninn, N
    ANNALS OF ONCOLOGY, 1998, 9 : 162 - 162
  • [6] Initial clinical trial and pharmacokinetics of Thymitaq(TM) (AG337) by 10-day continuous infusion in patients with advanced solid tumors
    Creaven, PJ
    Pendyala, L
    Meropol, NJ
    Clendeninn, NJ
    Wu, EY
    Loewen, GM
    Proefrock, A
    Johnston, A
    Dixon, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (02) : 167 - 170
  • [7] Preformulation studies for the development of a parenteral liquid formulation of an antitumor agent, AG337
    Li, SH
    Zamansky, I
    Orlov, I
    Tyle, P
    Roy, SD
    PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, 1997, 51 (05): : 181 - 186
  • [8] Initial clinical trial and pharmacokinetics of Thymitaq(TM) (AG337) by 10-day continuous infusion in patients with advanced solid tumors
    Creaven P.J.
    Pendyala L.
    Meropol N.J.
    Clendeninn N.J.
    Wu E.Y.
    Loewen G.M.
    Proefrock A.
    Johnston A.
    Dixon M.
    Cancer Chemotherapy and Pharmacology, 1997, 41 (2) : 167 - 170
  • [9] Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
    Hughes, AN
    Rafi, I
    Griffin, MJ
    Calvert, AH
    Newell, DR
    Calvete, JA
    Johnston, A
    Clendeninn, N
    Boddy, AV
    CLINICAL CANCER RESEARCH, 1999, 5 (01) : 111 - 118
  • [10] Solid-state characterization of a novel chemotherapeutic drug
    Marini, A
    Berbenni, V
    Bruni, G
    Maggioni, A
    Cofrancesco, P
    Sinistri, C
    Orlandi, A
    Villa, M
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (03) : 577 - 584